Orexigen (OREX) Catches Bids as Arena (ARNA) Continues Higher
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Join SI Premium – FREE
Orexigen Therapeutics (Nasdaq: OREX) shares are also ticking higher along with peer Arena Pharma (Nasdaq: ARNA) Tuesday as Arenas PDUFA for lorcaserin is coming up on June 27th.
Currently, Orexigen is enrolling patients to evaluate cardiovascular risk for its obesity drug, Contrave. Rejected by the FDA last year, Orexigen plans to file again in 2014.
Option implied volatility is up 4.6 percent on the session from Monday's close and up 118 percent over its trailing annual daily average.
Shares are 8.4 percent higher on the session Tuesday, comparable with Arena, which is up 8.7 percent.
At $3.54, shares are approaching the 50- and 100-day SMAs, which are both currently at $3.63.
Currently, Orexigen is enrolling patients to evaluate cardiovascular risk for its obesity drug, Contrave. Rejected by the FDA last year, Orexigen plans to file again in 2014.
Option implied volatility is up 4.6 percent on the session from Monday's close and up 118 percent over its trailing annual daily average.
Shares are 8.4 percent higher on the session Tuesday, comparable with Arena, which is up 8.7 percent.
At $3.54, shares are approaching the 50- and 100-day SMAs, which are both currently at $3.63.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Solaris Energy Infrastructure (SEI) call put ratio 3.1 calls to 1 put with a focus on August calls as share price up 7.7%
- Pfizer (PFE) call put ratio 1.1 calls to 1 put into quarter results
- Merck (MRK) call put ratio 1.2 calls to 1 put into quarter results
Create E-mail Alert Related Categories
Insiders' Blog, Momentum Movers, OptionsRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
